CuraTeQ Biologics, a wholly owned subsidiary of Aurobindo Pharma, has secured a Notice of Compliance (NOC) from Health Canada for its bevacizumab biosimilar, Bevqolva. The approval from Health Canada’s Biologics and Radiopharmaceutical Drugs Directorate (BRDD) grants formal marketing authorisation, confirming the biosimilar meets the regulatory standards for safety, efficacy, and quality comparable to the reference biologic drug.
Bevacizumab, a humanised monoclonal antibody, functions by inhibiting angiogenesis, the formation of new blood vessels, through blocking vascular endothelial growth factor A (VEGF-A). This mechanism is crucial in slowing tumour vascular growth and is used in the treatment of multiple cancers, including colorectal and lung cancer. The originator product, Avastin, is marketed by Roche/Genentech and is available in 100 mg and 400 mg formulations.
In 2025, Bevqolva received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) and was commercially launched for patients across the UK. The product is also under review by the Committee for Medicinal Products for Human Use (CHMP) with the European Medicines Agency. Additionally, CuraTeQ Biologics has two more biosimilar applications currently under review by Health Canada.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).